Teen Depression
Methodology & AI Transparency ⓘ
Teen Depression Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is depression in teens? Depression in teens (ages 13-17) is a serious medical illness.
- 2 Real-world patient consensus: Mapped to Depression, Bipolar & Mood Disorders under ICD-10-CM F32.2 for Teen Depression clinical workups.
- 3 Typical cash cost range: Workup highlights for Teen Depression (F32.2): safety/support screening [Teen Depression F32.2].
- 4 Top reported side effects / signs: Follow-up benchmark in Teen Depression: maintaining TSH & Free in Teen Depression (F32.2: T4 Rule-Out) within TSH 0.8 – 2.5 mIU/L (F32.2).
Ask our AI Specialists anything about Teen Depression
What Is Teen Depression?
What is depression in teens? Depression in teens (ages 13-17) is a serious medical illness. It's more than just a feeling of being sad or "blue" for a few days. It is an intense feeling of sadness, hopelessness, and anger or frustration that lasts much longer. These feelings make it hard for you to function normally and do your usual activities. You may also have trouble focusing and have no motivation or energy. Depression can make you feel like it is hard to enjoy life or even get through the day. What causes depression in teens? Many factors may play a role in depression, including: Genetics. Depression can run in families. Brain biology and chemistry. Hormones.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Teen Depression (code F32.2) is monoaminergic (serotonin [Teen Depression F32.2], Cross-referenced with NIH MeSH (Depression), which Depression, Bipolar & Mood Disorders clinicians address while surveilling TSH & Free in Teen Depression (F32.2: T4 Rule-Out) (TSH 0.8 – 2.5 mIU/L (F32.2)).
Common Symptoms & Clinical Signs
- • Genetics. Depression can run in families
- • Brain biology and chemistry
- • Presentation of Teen Depression (F32.2): disrupted sleep architecture [Teen Depression F32.2]
- • Secondary Teen Depression clinical sign: slowed concentration, indecisiveness, in Teen Depression (F32.2: and physical heaviness)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Teen Depression Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F32.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: TSH & Free in Teen Depression (F32.2: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F32.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Teen Depression (F32.2: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F32.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Teen Depression (F32.2: Score) | < 4 (clinical remission) (F32.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Teen Depression
Treatment selection for Teen Depression depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Teen Depression)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| When Antidepressants Aren't Enough: Can Adding SAMe Help Lift Stubborn Depression? SAMe may provide relief of depression symptoms similar to imipramine or escitalopram. General hospital psychiatry • 2024-01-15 • Meta-Analysis | N = 1,522 | 99/100 | PMID 38199136 ↗ |
| New Insights on Individualized fMRI connectivity defines signatures of antidepressant and placebo: What a 296-Participant Study Found Our findings demonstrated that through the removal of common FC components, individualization of FC metrics enhanced the prediction performance compared to raw FC. Molecular psychiatry • 2023-06-15 • Randomized Controlled Trial | N = 296 | 93/100 | PMID 36732585 ↗ |
| New Insights on Randomized, gold-standard blind comparison of aripiprazole/sertraline combination: What a 412-Participant Study Found In patients with MDD who showed an inadequate response to treatment with sertraline 100 mg/day, ASC was efficacious and well tolerated. Psychiatry and clinical neurosciences • 2018-08-15 • Randomized Controlled Trial | N = 412 | 93/100 | PMID 29660207 ↗ |
| New Insights on Adjunctive Cariprazine for the Treatment of Patients With depression: A: What a 249-Participant Study Found Adjunctive cariprazine at 1.5 mg/day demonstrated efficacy in reducing depressive symptoms in adults with depression and inadequate response to antidepressants alone. The American journal of psychiatry • 2023-03-01 • Phase III Randomized Trial | N = 249 | 88/100 | PMID 36789515 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in These novel data support semaglutide 2.4 mg as an efficacious obesity treatment in adolescents with obesity and advance its application by showing associated improvements in insulin sensitivity, glycemic measures, ALT, and... Diabetes care • 2026-06-01 • Phase III Randomized Trial | N = 129 | 88/100 | PMID 41296499 ↗ |
Teen Depression Patient Community & “People Like Me” Threads
Filter Teen Depression community threads and patient logs by age, biological sex, dosage, and treatment duration.